Patented Cxbladder tests are supported by strong clinical evidence and target a US$10.8b global market, with Medicare re-coverage and commercial payer adoption as key catalysts. FY26 saw revenue decline and increased losses, but cash burn was reduced and a NZ$24m capital raise is underway to support operations and growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.